Byrne Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$647K Sell
26,848
-2,863
-10% -$74.9K 0.35% 70
2026
Q1
$834K Sell
29,711
-839
-3% -$22.3K 0.49% 58
2025
Q4
$761K Buy
+30,550
New +$770K 0.42% 67
2025
Q3
Hold
0
60
2025
Q2
Sell
-29,600
Closed -$690K 59
2025
Q1
$750K Buy
29,600
+738
+3% +$19.3K 0.55% 53
2024
Q4
$766K Sell
28,862
-1,638
-5% -$44.4K 0.54% 56
2024
Q3
$883K Sell
30,500
-2,165
-7% -$63.2K 0.6% 54
2024
Q2
$908K Buy
+32,665
New +$899K 0.65% 49
2024
Q1
Hold
0
50
2023
Q4
Sell
-39,413
Closed -$1.19M 44
2023
Q3
$1.31M Sell
39,413
-1,390
-3% -$49.2K 1.08% 25
2023
Q2
$1.5M Buy
40,803
+750
+2% +$29.2K 0.97% 19
2023
Q1
$1.63M Sell
40,053
-635
-2% -$27.4K 1.17% 13
2022
Q4
$2.08M Sell
40,688
-1,535
-4% -$73.6K 1.51% 10
2022
Q3
$1.85M Buy
42,223
+170
+0.4% +$8.26K 1.42% 11
2022
Q2
$2.21M Sell
42,053
-150
-0.4% -$7.64K 1.63% 13
2022
Q1
$2.19M Buy
42,203
+1,675
+4% +$86.9K 1.36% 18
2021
Q4
$2.39M Buy
+40,528
New +$2.01M 1.55% 13

Other funds holding PFE

Byrne Asset Management's PFE Position: Q2 2026 in Review

Byrne Asset Management reduced its Pfizer (PFE) stake by 9.6% in Q2 2026, selling an estimated $74.9K and leaving 26,848 shares worth $647K. The position accounts for 0.35% of the portfolio, ranked #70.

Byrne Asset Management first reported a position in PFE in Q4 2021 and has held it in 15 quarters since. The position peaked at $2.39M in Q4 2021. 900 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Byrne Asset Management held 26,848 shares of Pfizer worth $647K as of Q2 2026.
  • Byrne Asset Management sold 2,863 Pfizer shares in Q2 2026, an estimated $74.9K.
  • Pfizer made up 0.35% of Byrne Asset Management's portfolio in Q2 2026, its #70 holding.
  • Byrne Asset Management first reported a position in Pfizer in Q4 2021 and has held it in 15 quarters since.
  • Byrne Asset Management's Pfizer position peaked at $2.39M in Q4 2021.
  • 900 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.